STUDY DESIGN: Secreted Protein, Acidic, and Rich in Cysteine (SPARC)-null mice were examined for behavioral signs of chronic low back and/or radicular pain. OBJECTIVE: to assess SPARC-null mice as an animal model of chronic low back and/or radicular pain caused by degenerative disc disease. SUMMARY OF BACKGROUND DATA: degeneration of intervertebral discs is a major cause of chronic low back and adicular pain in humans. Inactivation of the SPARC gene in mice results in premature intervertebral disc degeneration. The effect of disc degeneration on behavioral measures of chronic pain has not been evaluated in this model. METHODS: cohorts of young and old (3 and 6-12 months, respectively) SPARC-null and wild-type control mice were screened for behavioral indices of low back and/or radiating pain. Sensitivity to mechanical, cold and heat stimuli, locomotor impairment, and movement-evoked hypersensitivity were determined. Animals were challenged with 3 analgesic agents with different mechanisms: morphine, dexamethasone, and gabapentin. RESULTS: SPARC-null mice showed signs of movement-evoked discomfort as early as 3 months of age. Hypersensitivity to cold stimuli on both the lower back and hindpaws developed with increasing age. SPARC-null mice had normal sensitivity to tactile and heat stimuli, and locomotor skills were not impaired. The hypersensitivity to cold was reversed by morphine, but not by dexamethasone or gabapentin. CONCLUSION: SPARC-null mice display behavioral signs consistent with chronic low back and radicular pain that we attribute to intervertebral disc degeneration. We hypothesize that the SPARC-null mouse is useful as a model of chronic back pain due to degenerative disc disease.
STUDY DESIGN:Secreted Protein, Acidic, and Rich in Cysteine (SPARC)-null mice were examined for behavioral signs of chronic low back and/or radicular pain. OBJECTIVE: to assess SPARC-null mice as an animal model of chronic low back and/or radicular pain caused by degenerative disc disease. SUMMARY OF BACKGROUND DATA: degeneration of intervertebral discs is a major cause of chronic low back and adicular pain in humans. Inactivation of the SPARC gene in mice results in premature intervertebral disc degeneration. The effect of disc degeneration on behavioral measures of chronic pain has not been evaluated in this model. METHODS: cohorts of young and old (3 and 6-12 months, respectively) SPARC-null and wild-type control mice were screened for behavioral indices of low back and/or radiating pain. Sensitivity to mechanical, cold and heat stimuli, locomotor impairment, and movement-evoked hypersensitivity were determined. Animals were challenged with 3 analgesic agents with different mechanisms: morphine, dexamethasone, and gabapentin. RESULTS:SPARC-null mice showed signs of movement-evoked discomfort as early as 3 months of age. Hypersensitivity to cold stimuli on both the lower back and hindpaws developed with increasing age. SPARC-null mice had normal sensitivity to tactile and heat stimuli, and locomotor skills were not impaired. The hypersensitivity to cold was reversed by morphine, but not by dexamethasone or gabapentin. CONCLUSION:SPARC-null mice display behavioral signs consistent with chronic low back and radicular pain that we attribute to intervertebral disc degeneration. We hypothesize that the SPARC-null mouse is useful as a model of chronic back pain due to degenerative disc disease.
Authors: K Luoma; H Riihimäki; R Luukkonen; R Raininko; E Viikari-Juntura; A Lamminen Journal: Spine (Phila Pa 1976) Date: 2000-02-15 Impact factor: 3.468
Authors: Lawrence M Boyd; William J Richardson; Kyle D Allen; Charlene Flahiff; Liufang Jing; Yefu Li; Jun Chen; Lori A Setton Journal: Arthritis Rheum Date: 2008-01
Authors: Changgui Shi; Sujun Qiu; Scott M Riester; Vaskar Das; Bingqian Zhu; Atiyayein A Wallace; Andre J van Wijnen; Fackson Mwale; James C Iatridis; Daisuke Sakai; Gina Votta-Velis; Wen Yuan; Hee-Jeong Im Journal: J Orthop Res Date: 2018-03-14 Impact factor: 3.494
Authors: Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone Journal: Neuropharmacology Date: 2015-08-06 Impact factor: 5.250
Authors: Maral Tajerian; Sebastian Alvarado; Magali Millecamps; Thomas Dashwood; Kathleen M Anderson; Lisbet Haglund; Jean Ouellet; Moshe Szyf; Laura S Stone Journal: Mol Pain Date: 2011-08-25 Impact factor: 3.395